DC7056 |
AMG-208
Featured
|
AMG-208 is a potent small molecular c-Met inhibitor with an IC50 of 9.3 nM. |
|
DC8845 |
AMG337
Featured
|
AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor. AMG 337 inhibits MET kinase activity with an IC50 of < 5nM in enzymatic assays. |
|
DC7001 |
AMG-47a
Featured
|
AMG-47a is a potent inhibitor of Lck and T cell proliferation; exhibits anti-inflammatory activity (ED50 = 11 mg/kg) in the anti-CD3 induced production of IL-2 in mice. |
|
DC7324 |
Amuvatinib (MP-470)
Featured
|
Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. |
|
DC8029 |
ANA-12
Featured
|
ANA-12 is a potent and selective TrkB antagonist with anxiolytic and antidepressant activity in mice. |
|
DC1020 |
Ponatinib (AP24534)
Featured
|
AP24534 is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively. |
|
DC4101 |
Apatinib Mesylate
Featured
|
Apatinib (YN968D1) is an orally bioavailable, selective VEGFR2 inhibitor with IC50 of 1 nM. |
|
DC10975 |
ARQ-531
Featured
|
ARQ-531 is a potent, reversible, orally available inhibitor of both wild type and C481S-mutant BTK kinase with IC50 of 0.85 and 0.39 nM, |
|
DC8486 |
Varlitinib(ARRY-334543) |
ARRY-334543 is a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases. |
|
DC7359 |
Asp-3026
Featured
|
ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM. |
|
DC7360 |
AST-1306 |
AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases. |
|
DC10921 |
ATH686
Featured
|
ATH686 (ATH-686) is a potent and selective, second-generation inhibitor of mutant FLT3 protein kinase. |
|
DC8253 |
AV-412(MP-412) |
AV-412(MP-412) is a potent dual inhibitor of EGFR and ErbB2(IC50=19 nM) tyrosine kinases, including the mutant EGFR(L858R IC50=0.51 nM, T790M IC50=0.79 nM); inhibits autophosphorylation of EGFR and ErbB2 with IC(50) of 43 and 282 nM, respectively. |
|
DC10009 |
Avitinib free base
Featured
|
Avitinib is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. |
|
DC10008 |
Avitinib maleate
Featured
|
Avitinib is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. |
|
DC5014 |
AVL-292
Featured
|
AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk currently being evaluated in a Phase 1b clinical trial in relapsed. |
|
DCAPI1524 |
Axitinib
Featured
|
Axitinib is a non-selective receptor kinase inhibitor of Flt and Flk proteins. This compound also inhibits VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β and c-KIT with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively. Axitinib is studied as an ant |
|
DC7746 |
AZ191
Featured
|
AZ191 is a potent and selective DYRK1B inhibitor with IC50 of 17 nM, about 5- and 110-fold selectivity over DYRK1A and DYRK2, respectively. |
|
DC8052 |
AZ5104
Featured
|
AZ5104 is an active circulating metabolite of AZD9291. |
|
DC7799 |
AZD2932
Featured
|
AZD-2932 is a high affinity inhibitor of VEFGR-2 and PDGFR. |
|
DC8472 |
AZD-3759
Featured
|
AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. |
|
DC1075 |
AZD4547
Featured
|
AZD4547 is a novel selective FGFR inhibitor targeting FGFR1, FGFR2, and FGFR3 with IC50 of of 0.2 nM, 2.5 nM, and 1.8 nM, respectively. |
|
DC12490 |
AZD7507
Featured
|
AZD7507 (AZD-7507) is a potent, selective, orally available CSF-1R (c-FMS) with IC50 of 32 nM. |
|
DC7006 |
AZD-9291(Osimertinib)
Featured
|
AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM). |
|
DC8462 |
AZD-9291 mesylate (Osimertinib,Mereletinib)
Featured
|
AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM). |
|
DC10112 |
AZD9362 |
AZD-9362 is dual IGF-IR/InsR inhibitor. |
|
DC2013 |
Bafetinib (INNO-406)
Featured
|
Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM and 19 nM, respectively. |
|
DC9632 |
BAY 61-3606 (dihydrochloride)
Featured
|
BAY 61-3606 2Hcl is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src.
|
|
DC10660 |
BAY 61-3606 free base
Featured
|
BAY 61-3606 is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src.
|
|
DC10058 |
BBT594 |
BBT594 (NVP-BBT594), is potent and selective inhibitor of RET and JAK2. |
|